Impact and programmatic implications of routine viral load monitoring in swaziland

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue 1, 2014, Pages 45-51

  Jobanputra, Kiran ^a   Parker, Lucy Anne ^a   Azih, Charles ^b   Okello, Velephi ^b   Maphalala, Gugu ^c   Jouquet, Guillaume ^a   Kerschberger, Bernhard ^a   Mekeidje, Calorine ^a   Cyr, Joanne ^a   Mafikudze, Arnold ^a   Han, Win ^a   Lujan, Johnny ^a   Teck, Roger ^a   Antierens, Annick ^a   Van Griensven, Johan ^d   Reid, Tony ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b Government of the Kingdom of Eswatini   (Switzerland)

^c Swaziland National Reference Laboratory   (Switzerland)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

adherence; ART monitoring; cost; feasibility; secondline; viral load

Indexed keywords

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MICROBIOLOGICAL EXAMINATION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SWAZILAND; TREATMENT OUTCOME; VIRUS LOAD; COST BENEFIT ANALYSIS; COUNSELING; ECONOMICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MEDICATION COMPLIANCE; NONPARAMETRIC TEST; VIROLOGY; YOUNG ADULT;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; COUNSELING; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SWAZILAND; VIRAL LOAD; YOUNG ADULT;

EID: 84906080172     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000224     Document Type: Article

References (17)

1. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach. World Health Organization, Geneva, 2013.
2. Kunutsor S, Walley J, Muchuro S, et al. Improving adherence to anti-retroviral therapy in sub-Saharan African HIV-positive populations: an enhanced adherence package. AIDS Care. 2012;24:1308-1315.
3. Keiser O, Chi BH, Gsponer T, et al. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS. 2011;25:1761-1769.
4. Sigaloff KCE, Hamers RL, Wallis CL, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011;58:23-31.
5. Keebler D, Revill P, Braithwaite S, et al. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. Lancet Glob Health. 2014;2:e35-e43.
6. MSF Access Campaign. How Low Can We Go? Pricing for HIV Viral Load Testing in Low-And Middle-Income Countries. Geneva: MSF; 2013.
7. Bonner K, Mezochow A, Roberts T, et al. Viral load monitoring as a tool to reinforce adherence: a systematic review. J Acquir Immune Defic Syndr. 2013;64:74-78.
8. Davies MA, Moultrie H, Eley B, et al. Virologic failure and second-line antiretroviral therapy in children in South Africa-The IeDEA, Southern Africa Collaboration. J Acquir Immune Defic Syndr. 2011;56:270-278.
9. Orrell C, Harling G, Lawn S. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther. 2007;12: 83-88. Available at: http://www.intmedpress.com/servefile.cfm? suid=4424b208-e825-4c65-96aa-8c9af65cfb60. Accessed March 20, 2013.
10. Johnston V, Fielding KL, Churchyard G. Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment programme. J Acquir Immune Defic Syndr. 2012;61:1-19.
11. Keiser O, Tweya H, Boulle A, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS. 2009;23:1867-1874.
12. Nkambule R. SHIMS (Swaziland HIV Incidence Measurement Survey)-Findings. ICAP, New York; 2012.
13. Strategic Information Department-Ministry of Health-Kingdom of Swaziland. ART Program Annual Report, 2012. Ministry of Health, Mbabane, 2012.
14. Maphalala G, Okello V, Mndzebele S, et al. Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006. Antivir Ther. 2008;13(suppl 2):95-100. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/18575197. Accessed March 20, 2013.
15. Boyer S, March L, Kouanfack C, et al. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Lancet Infect Dis. 2013;13:577-586.
16. Auld AF, Mbofana F, Shiraishi RW, et al. Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One. 2011;6:e18453.
17. Landier J, Akonde A, Pizzocolo C, et al. Switch to second-line ART in West African routine care: incidence and reasons for switching. AIDS Care. 2011;23:75-78.